Integrated Wealth Concepts’s Protalix BioTherapeutics PLX Stock Holding History

Integrated Wealth Concepts’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.51K	Buy	+2,793	New	+$5.92K	﹤0.01%	4831

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Integrated Wealth Concepts's PLX Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 2,793 shares worth $6.51K. The stake represents ﹤0.01% of the portfolio and ranks #4831 among its holdings.

102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Integrated Wealth Concepts held 2,793 shares of Protalix BioTherapeutics worth $6.51K as of Q2 2026.
Protalix BioTherapeutics was a new Integrated Wealth Concepts position in Q2 2026.
Protalix BioTherapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #4831 holding.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.